Cardiovascular Systems, Inc.

296 articles about Cardiovascular Systems, Inc.

• Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial

  4/3/2023

  Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company completed the enrollment of its 2,000 patient ECLIPSE coronary trial.

• Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

  2/8/2023

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022.

• Abbott to Acquire Cardiovascular Systems, Inc.

  2/8/2023

  Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.

• Cardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023

  1/19/2023

  Cardiovascular Systems, Inc. (NASDAQ: CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results.

• Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study

  1/11/2023

  Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) announced today the company has initiated the KAIZEN clinical study of its Diamondback 360© Peripheral Orbital Atherectomy System (OAS) for the treatment of calcified plaque in patients with peripheral artery disease (PAD).

• Cardiovascular Systems, Inc. Announces FDA 510(k) Submission of Innova Vascular, Inc.’s Thrombectomy System

  1/4/2023

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that Innova Vascular, Inc. (Innova) has submitted a 510(k) Premarket Notification to the U.S. Food and Drug Administration (FDA) for its thrombectomy devices intended to treat peripheral vascular disease.

• Cardiovascular Systems, Inc. to Participate in Two November 2022 Healthcare Conferences

  11/9/2022

  Cardiovascular Systems, Inc. announced that management plans to present and host investor meetings at the Stifel 2022 Healthcare Conference and will host investor meetings at the Canaccord Genuity MedTech Conference.

• Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems

  10/17/2022

  Cardiovascular Systems, Inc. announced today the full market release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems (2.00 Max Crown).

• Cardiovascular Systems, Inc. Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

  8/3/2022

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with vascular and coronary artery disease, today reported financial results for its fourth quarter and full year, ended June 30, 2022.

• Cardiovascular Systems, Inc. to Release Fiscal 2022 Fourth Quarter Results on August 2, 2022

  7/13/2022

  Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) will release fourth-quarter results the evening of August 2. In lieu of hosting a quarterly earnings conference call, CSI management will discuss fourth-quarter results at the beginning of its capital markets day on August 3.

• Cardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial Results

  5/4/2022

  Cardiovascular Systems, Inc. today reported financial results for its third quarter, ended March 31, 2022.

• Cardiovascular Systems, Inc. to Host Earnings Conference Call on May 4, 2022

  4/13/2022

  Cardiovascular Systems, Inc. plans to announce its operating results for the quarter ended March 31, 2022 before the market opens on Wednesday, May 4, 2022, and will host a conference call at 8:00 a.m. CT that day to discuss those results.

• Cardiovascular Systems, Inc. to Participate at Two Upcoming Healthcare Conferences

  3/22/2022

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at two upcoming healthcare conferences.

• Cardiovascular Systems, Inc. Announces First In-Human Experience With Company’s Propel™ Percutaneous Ventricular Assist Device

  3/16/2022

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), announced today the first in-human experience with Propel™, its first-generation percutaneous ventricular assist device (pVAD), offering hemodynamic support for patients undergoing high-risk percutaneous coronary interventions (HR-PCI).

• Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon

  3/9/2022

  Cardiovascular Systems, Inc. announced today the start of enrollment in a first in-human trial of the peripheral everolimus drug-coated balloon (DCB) being developed by Chansu Vascular Technologies, LLC (CVT).

• Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical Officer

  3/4/2022

  Cardiovascular Systems, Inc. today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer.

• Cardiovascular Systems, Inc. Announces Partnership With Innova Vascular, Inc. to Develop Full Line of Thrombectomy Devices

  2/23/2022

  Cardiovascular Systems, Inc. announced today it has partnered with Innova Vascular, Inc.

• Cardiovascular Systems, Inc. Reports Fiscal 2022 Second Quarter Financial Results

  2/3/2022

  Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, reported financial results for its second quarter, ended December 31, 2021.

• Cardiovascular Systems, Inc. to Participate at SVB Leerink 2022 Global Healthcare Conference

  1/27/2022

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the SVB Leerink 2022 Global Healthcare Conference.

• Cardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex® Scoring Balloon

  1/20/2022

  Cardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex ® Scoring Balloon.